Bradykinin

Phase 1Small molecule

VVanderbilt University

Bradykinin is one of 94 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery DiseaseActive, not recruiting

AngioedemaActive, not recruiting

ObesityActive, not recruiting

Coronary Artery DiseasePhase 1

Active, not recruiting

AngioedemaPreclinical

Active, not recruiting

ObesityPreclinical

Active, not recruiting

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

Actemra

Roche

Preclinical

2 2

Avapro

Sanofi

Preclinical

1 3

Amidate

Pfizer

Preclinical

—4

Calciferol

Alnylam Pharmaceuticals

Adenocard

Activella

Colcrys

Alnylam Pharmaceuticals

Preclinical

—8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 9

Cetrotide

EMD Serono

Preclinical

2 10

Advil

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Transplant Recipient2 trials

Brachial Artery t-PA Release in Heart Transplant Recipients

Withdrawn·VVanderbilt University·N/A·NCT00780637

Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients

Withdrawn·VVanderbilt University·N/A·NCT00780377

Coronary Artery Disease1 trial

Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease

Terminated·VVanderbilt University·Phase 1·NCT00868855·16 enrolled

Humans1 trial

Endothelial Hyperpolarization in Humans

Terminated·EEmory University·Phase 2·NCT00166166·174 enrolled

Obesity1 trial

Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation

Terminated·VVanderbilt University·N/A·NCT00780481·13 enrolled

Angioedema1 trial

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Completed·VVanderbilt University·N/A·NCT01413542·44 enrolled

2 more indications

Aspirin1 trial

Comparative Effects of Aspirin and NHP-544C

Completed·VVanderbilt University·N/A·NCT02189122·61 enrolled

ARB1 trial

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

Terminated·VVanderbilt University Medical Center·Phase 4·NCT03738878·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Bradykinin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bradykinin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bradykinin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VVanderbilt University

Bradykinin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Transplant Recipient2 trials

Coronary Artery Disease1 trial

Humans1 trial

Obesity1 trial

Angioedema1 trial

Aspirin1 trial

ARB1 trial

References

Drug Info

Quick Facts

Related News